Breaking News Instant updates and real-time market news.

RHHBY

Roche

$30.56

0.073 (0.24%)

04:52
10/11/16
10/11
04:52
10/11/16
04:52

Genentech sBLA for Lucentis accepted by FDA, granted Priority Review

Genentech, a member of the Roche Group, announced that the FDA has accepted a supplemental Biologics License Application, or sBLA, and granted Priority Review for Lucentis for the treatment of myopic choroidal neovascularization, or mCNV, a complication of severe near-sightedness that can lead to blindness. The sBLA is based on results from the Phase III RADIANCE study that demonstrated treatment with Lucentis provided superior visual acuity gains in people with mCNV compared to verteporfin photodynamic therapy, the only treatment currently approved by the FDA for mCNV.

  • 19

    Oct

  • 06

    Nov

  • 10

    Nov

RHHBY Roche
$30.56

0.073 (0.24%)

09/01/16
BMOC
09/01/16
NO CHANGE
BMOC
Bristol-Myers has negative read through from Roche data, says BMO Capital
BMO Capital analyst Alex Arfaei says that the positive data on Roche's (RHHBY) TECENTRIQ for second line NSCLC is negative for Bristol-Myers' (BMY) cancer drug, Opdivo. The analyst does not think that TECENTRIQ's results will be superior to that of Opdivo, but he believes that Roche's drug appears to have "a significant" benefit in PD-L1 positive patients." He predicts that Roche's drug could take "meaningful market share, particularly outside of the U.S." The analyst keeps a Market Perform rating on Bristol-Myers.
09/07/16
09/07/16
NO CHANGE

BioLineRx partnering with Roche company in cancer therapy research
BioLineRx (BLRX) has entered into a collaboration with Genentech, a member of the Roche (RHHBY) Group, to support several Phase 1b studies investigating BioLineRx's BL-8040 in combination with Atezolizumab, Genentech's anti-PDL1 cancer immunotherapy, in multiple cancer indications. The Phase 1b studies will evaluate the clinical response, safety and tolerability of the combination of these therapies, as well as multiple pharmacodynamic parameters, in hematologic malignancies and solid tumors. Under the agreement, Genentech will sponsor and conduct several Phase 1b trials in multiple solid cancer indications. In addition, BioLineRx will sponsor and conduct a Phase 1b study in acute myeloid leukemia patients. The studies are designed to evaluate the safety and efficacy of the combination of BL-8040 and Atezolizumab. Upon completion of the studies, both parties will have the option to expand the collaboration to include a pivotal registration study. Additional details of the collaboration were not disclosed.
09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.

TODAY'S FREE FLY STORIES

STC

Stewart

09:34
12/05/16
12/05
09:34
12/05/16
09:34
Downgrade
Stewart rating change  »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNA

Snap-On

09:33
12/05/16
12/05
09:33
12/05/16
09:33
Recommendations
Snap-On analyst commentary  »

Snap-On results poised to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AETI

American Electric Tech.

$1.75

-0.05 (-2.78%)

09:32
12/05/16
12/05
09:32
12/05/16
09:32
Hot Stocks
American Electric Tech. unit awarded contract in Trinidad »

American Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWB

Great Western

09:31
12/05/16
12/05
09:31
12/05/16
09:31
Conference/Events
Great Western management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

HIL

Hill International

09:31
12/05/16
12/05
09:31
12/05/16
09:31
Hot Stocks
Hill International receives $15.5M facilities management contract from ADNOC »

Hill International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$59.25

0.05 (0.08%)

, GOOG

Alphabet

$750.50

2.58 (0.34%)

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Periodicals
Microsoft's Home Hub to go beyond Google Home, Amazon Echo, Windows Central says »

Microsoft's rumored…

MSFT

Microsoft

$59.25

0.05 (0.08%)

GOOG

Alphabet

$750.50

2.58 (0.34%)

GOOGL

Alphabet Class A

$764.46

0.13 (0.02%)

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

CLC

Clarcor

, PH

Parker-Hannifin

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Recommendations
Clarcor, Parker-Hannifin analyst commentary  »

Clarcor price target…

CLC

Clarcor

PH

Parker-Hannifin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 19

    Dec

  • 20

    Dec

ASUR

Asure Software

$8.48

0.21 (2.54%)

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Hot Stocks
Asure Software appoints Eyal Goldstein as Chief Revenue Officer »

Asure Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

BDC

Belden

09:30
12/05/16
12/05
09:30
12/05/16
09:30
Earnings
Belden sees FY16 adjusted EPS $5.20-$5.30, consensus $5.24 »

Sees FY16 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

09:30
12/05/16
12/05
09:30
12/05/16
09:30
General news
Chicago Fed dove Evans sees growth picking up »

Chicago Fed dove Evans…

BDC

Belden

09:29
12/05/16
12/05
09:29
12/05/16
09:29
Earnings
Belden sees Q4 adjusted EPS $1.36-$1.46, consensus $1.40 »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

BDC

Belden

09:28
12/05/16
12/05
09:28
12/05/16
09:28
Hot Stocks
Breaking Hot Stocks news story on Belden »

Belden to confirm Q4,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

INWK

InnerWorkings

$9.20

0.25 (2.79%)

09:28
12/05/16
12/05
09:28
12/05/16
09:28
Hot Stocks
InnerWorkings, GateHouse Media announce multi-year affiliation »

InnerWorkings and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

STC

Stewart

09:28
12/05/16
12/05
09:28
12/05/16
09:28
Downgrade
Stewart rating change  »

Stewart downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

MeetMe

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Earnings
MeetMe sees FY revenue $74.5M-$76M, consensus $75.11M »

Adjusted EBITDA for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

OPTT

Ocean Power

$3.23

0.04 (1.25%)

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Hot Stocks
Ocean Power, Sonalysts announce joint marketing agreement »

Ocean Power Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIMO

Gigamon

, VZ

Verizon

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Recommendations
Gigamon, Verizon, AT&T, T-Mobile, Amazon.com analyst commentary  »

Gigamon setting up well…

GIMO

Gigamon

VZ

Verizon

T

AT&T

TMUS

T-Mobile

$54.44

0.18 (0.33%)

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

  • 13

    Dec

  • 24

    Jan

MEET

MeetMe

09:27
12/05/16
12/05
09:27
12/05/16
09:27
Earnings
MeetMe sees Q4 revenue $27.5M-$29M, consensus $28.2M »

Adjusted EBITDA for the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

MOS

Mosaic

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Recommendations
Mosaic analyst commentary  »

Mosaic estimates lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEET

MeetMe

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Hot Stocks
MeetMe reports U.S. mobile CPMs up 14% y/y in November »

MeetMe said that its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

MEET

MeetMe

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Hot Stocks
Breaking Hot Stocks news story on MeetMe »

MeetMe reiterates Q4, FY…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

MCD

McDonald's

09:26
12/05/16
12/05
09:26
12/05/16
09:26
Technical Analysis
McDonald's extends its recent recovery »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FRP

FairPoint

$17.00

0.25 (1.49%)

, CNSL

Consolidated Communications

$28.38

0.11 (0.39%)

09:25
12/05/16
12/05
09:25
12/05/16
09:25
Hot Stocks
On The Fly: Pre-market Movers »

FairPoint Communications…

FRP

FairPoint

$17.00

0.25 (1.49%)

CNSL

Consolidated Communications

$28.38

0.11 (0.39%)

CHK

Chesapeake

BLCM

Bellicum Pharmaceuticals

$18.72

1.74 (10.25%)

MRVL

Marvell

$14.02

0.04 (0.29%)

KITE

Kite Pharma

$50.76

0.04 (0.08%)

CERC

Cerecor

$1.75

-0.24 (-12.06%)

ETP

Energy Transfer Partners

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 05

    Dec

  • 05

    Dec

  • 14

    Dec

ICE

IntercontinentalExchange

09:25
12/05/16
12/05
09:25
12/05/16
09:25
Hot Stocks
IntercontinentalExchange reports November futures ADV up 12% »

Intercontinental Exchange…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

QURE

uniQure

$5.68

-0.31 (-5.18%)

09:25
12/05/16
12/05
09:25
12/05/16
09:25
Conference/Events
uniQure to host investor breakfast meeting »

Investor breakfast…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 08

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.